## Quentin Bayard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2045565/publications.pdf

Version: 2024-02-01

687220 996849 1,016 16 13 15 citations h-index g-index papers 16 16 16 2057 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncology, The, 2022, 23, 161-171.	5.1	36
2	Structure, Dynamics, and Impact of Replication Stress–Induced Structural Variants in Hepatocellular Carcinoma. Cancer Research, 2022, 82, 1470-1481.	0.4	0
3	Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 1038-1046.	1.8	17
4	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. Journal of Hepatology, 2021, 74, 1155-1166.	1.8	54
5	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. Cancer Discovery, 2021, 11, 2524-2543.	7.7	41
6	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Medicine, 2021, 13, 113.	3.6	31
7	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology, 2021, 74, 816-834.	3.6	20
8	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology, 2020, 71, 164-182.	3.6	129
9	Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut, 2020, 69, 737-747.	6.1	78
10	Recurrent chromosomal rearrangements of <i>ROS1</i> , <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut, 2020, 69, 1667-1676.	6.1	17
11	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. Journal of Hepatology, 2020, 72, 924-936.	1.8	44
12	High Impact: The Role of Promiscuous Binding Sites in Polypharmacology. Molecules, 2019, 24, 2529.	1.7	9
13	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology, 2019, 157, 760-776.	0.6	141
14	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nature Communications, 2018, 9, 5235.	5.8	118
15	Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. Bioinformatics, 2018, 34, 3380-3381.	1.8	53
16	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nature Communications, 2017, 8, 1315.	5.8	228